CompletedPhase 2

Clinical Trial to Assess Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients With Multiple System Atrophy of the Parkinsonian Subtype (MSA-P)

United States174 participantsStarted 2009-12

Plain-language summary

To test the clinical effect of rasagiline on subjects with MSA of the parkinsonian subtype.

Age range30 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✕. Speech impairment as assessed by a score of ≥ 3 on UMSARS question 1
✕. Swallowing impairment as assessed by a score of ≥ 3 on UMSARS question 2
✕. Impairment in ambulation as assessed by a score of ≥ 3 on UMSARS question 7
✕. Falling more frequently than once per week as assessed by a score of ≥ 3 on UMSARS question 8

Change From Baseline to Week 48/Termination Visit in the Total Unified Multiple System Atrophy Rating Scale (UMSARS Part I and II)

Timeframe: Day 0 (baseline), Week 48

NCT IDNCT00977665

SponsorTeva Branded Pharmaceutical Products R&D, Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2011-10

Results submitted2015-02-10